Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAVEN: Venetoclax and Navitoclax in Relapsed/Refractory ALL
NCT05192889Phase 2Active, not recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Aug 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax, navitoclax in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), sponsored by St. Jude Children's Research Hospital. Started Aug 2022; status: active, not recruiting.
02
Drugs
venetoclaxnavitoclax
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT05192889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05192889.